NCT02615730View on ClinicalTrials.gov

PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
Advanced Gastric Adenocarcinoma
Interventions
DRUG

GSK2636771

Increasing dose levels of GSK2636771 (300 mg or 400 mg once daily)

DRUG

Paclitaxel

fixed dose of paclitaxel (80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle)

Trial Locations (1)

120-752

Severance Hospital, Yonsei University Health System, Yonsei Cancer Center, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT02615730 - PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma | Biotech Hunter | Biotech Hunter